Journal
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
Volume 8, Issue -, Pages 12-16Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ctro.2017.11.003
Keywords
Glioblastoma; Poly(ADP-ribose) polymerase; Olaparib; Radiotherapy; O6-methylguanine methyltransferase; Dose escalation; Radiosensitizer
Funding
- AstraZeneca
- Cancer Research UK [A20546]
- Brain Tumour Charity
- MRC [G0802755] Funding Source: UKRI
Ask authors/readers for more resources
Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy +/- temozolo mide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules. (C) 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and Oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
